Bessemer Group
FLNA

Bessemer Group’s Filana Therapeutics FLNA Stock Holding History

Bessemer Group’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-24
Closed – – 2623
2026
Q1 		$0 Hold
24
– – ﹤0.01% 2661
2025
Q4 		$0 Hold
24
– – ﹤0.01% 2692
2025
Q3 		$0 Buy
+24
New +$55 ﹤0.01% 2697
2024
Q4 		– Sell
-55
Closed -$2K – 2661
2024
Q3 		$2K Buy
+55
New +$1.27K ﹤0.01% 2262
2022
Q3 		– Sell
-150
Closed -$4K – 2148
2022
Q2 		$4K Hold
150
– – ﹤0.01% 1624
2022
Q1 		$6K Hold
150
– – ﹤0.01% 1482
2021
Q4 		$7K Hold
150
– – ﹤0.01% 1507
2021
Q3 		$9K Hold
150
– – ﹤0.01% 1412
2021
Q2 		$13K Buy
+150
New +$8.04K ﹤0.01% 1299

Other funds holding FLNA

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $1.92B AUM 70.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

Bessemer Group's FLNA Position: Q2 2026 in Review

Bessemer Group sold out of Filana Therapeutics (FLNA) in Q2 2026, closing a stake of 24 shares.

Bessemer Group first reported a position in FLNA in Q2 2021 and held it in 9 quarters. The position peaked at $13K in Q2 2021. 85 funds tracked by Wall St. Rank hold FLNA as of Q2 2026.

  • Bessemer Group reported no remaining Filana Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Bessemer Group sold 24 Filana Therapeutics shares in Q2 2026.
  • Bessemer Group first reported a position in Filana Therapeutics in Q2 2021 and held it in 9 quarters.
  • Bessemer Group's Filana Therapeutics position peaked at $13K in Q2 2021.
  • 85 funds tracked by Wall St. Rank held Filana Therapeutics as of Q2 2026.

Based on Bessemer Group's 13F filing for Q2 2026, filed 12 Aug 2026.